View Item 

Show simple item record

Application of the H2FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial
dc.contributor.authorMyhre, Peder L.
dc.contributor.authorVaduganathan, Muthiah
dc.contributor.authorClaggett, Brian L.
dc.contributor.authorLam, Carolyn S.P.
dc.contributor.authorDesai, Akshay S.
dc.contributor.authorAnand, Inder S.
dc.contributor.authorSweitzer, Nancy K.
dc.contributor.authorFang, James C.
dc.contributor.authorO’Meara, Eileen
dc.contributor.authorShah, Sanjiv J.
dc.contributor.authorShah, Amil M.
dc.contributor.authorLewis, Eldrin F.
dc.contributor.authorRouleau, Jean
dc.contributor.authorPitt, Bertram
dc.contributor.authorSolomon, Scott D.
dc.date.accessioned2019-11-12T16:21:14Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2019-11-12T16:21:14Z
dc.date.issued2019-10
dc.identifier.citationMyhre, Peder L.; Vaduganathan, Muthiah; Claggett, Brian L.; Lam, Carolyn S.P.; Desai, Akshay S.; Anand, Inder S.; Sweitzer, Nancy K.; Fang, James C.; O’Meara, Eileen; Shah, Sanjiv J.; Shah, Amil M.; Lewis, Eldrin F.; Rouleau, Jean; Pitt, Bertram; Solomon, Scott D. (2019). "Application of the H2FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial." European Journal of Heart Failure 21(10): 1288-1291.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/151972
dc.publisherJohn Wiley & Sons, Ltd
dc.titleApplication of the H2FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151972/1/ejhf1542_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151972/2/ejhf1542.pdf
dc.identifier.doi10.1002/ejhf.1542
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferencePitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383 – 1392.
dc.identifier.citedreferenceSepehrvand N, Alemayehu W, Dyck GJ, Dyck JR, Anderson T, Howlett J, Paterson I, McAlister FA, Ezekowitz JA. External validation of the H 2 F‐PEF model in diagnosing patients with heart failure and preserved ejection fraction. Circulation 2019; 139: 2377 – 2379.
dc.identifier.citedreferenceSegar MW, Patel KV, Berry JD, Grodin JL, Pandey A. Generalizability and implications of the H2FPEF score in a cohort of patients with heart failure with preserved ejection fraction. Circulation 2019; 139: 1851 – 1853.
dc.identifier.citedreferenceMyhre PL, Vaduganathan M, Claggett BL, Anand IS, Sweitzer NK, Fang JC, O’Meara E, Shah SJ, Desai AS, Lewis EF, Rouleau J, Pitt B, Pfeffer MA, Solomon SD. Association of natriuretic peptides and cardiovascular prognosis in heart failure with preserved fraction: secondary analysis of the TOPCAT randomized clinical trial. JAMA Cardiol 2018; 3: 1000 – 1005.
dc.identifier.citedreferenceGreene SJ, Hernandez AF, Sun JL, Butler J, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, O’Connor CM, Mentz RJ. Relationship between enrolling country income level and patient profile, protocol completion, and trial end points. Circ Cardiovasc Qual Outcomes 2018; 11:e004783.
dc.identifier.citedreferenceShah AM, Shah SJ, Anand IS, Sweitzer NK, O’Meara E, Heitner JF, Sopko G, Li G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2014; 7: 104 – 115.
dc.identifier.citedreferencePfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 2015; 131: 34 – 42.
dc.identifier.citedreferenceReddy YN, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence‐based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018; 138: 861 – 870.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf1542_am.pdf
Size:
392.2KB
Format:
PDF
View/Open
Name:
ejhf1542.pdf
Size:
555.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.